Advanced search
Publication Cover
Postgraduate Medicine Volume 131, 2019 - Issue 7
Submit an article Journal homepage
371
Views
8
CrossRef citations to date
0
Altmetric
Clinical Focus: Neurological & Psychiatric Disorders - Original Research

A retrospective observational study of rituximab treatment in multiple sclerosis patients in Cyprus

Eleni LeonidouNeurology Clinic C, The Cyprus Institute of Neurology and Genetics, Nicosia, CyprusView further author information
,
Marios PantzarisNeurology Clinic C, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus;The Cyprus School of Molecular Medicine, Nicosia, CyprusView further author information
,
Kleopas A. KleopaThe Cyprus School of Molecular Medicine, Nicosia, Cyprus;Neurology Clinic E, The Cyprus Institute of Neurology and Genetics, Nicosia, CyprusCorrespondence[email protected]
View further author information
,
Maria A. LoizidouDepartment of EM/Molecular Pathology, The Cyprus Institute of Neurology and Genetics, Nicosia, CyprusView further author information
,
Theodoros KyriakidesThe Cyprus School of Molecular Medicine, Nicosia, Cyprus;Neurology Clinic A, The Cyprus Institute of Neurology and Genetics, Nicosia, CyprusView further author information
&
Yiolanda P. ChristouNeurology Clinic D, The Cyprus Institute of Neurology and Genetics, Nicosia, CyprusView further author information
Pages 486-489 | Received 31 May 2019, Accepted 26 Jul 2019, Published online: 30 Jul 2019

References

  • Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007 Apr;17(2):210–218.
  • Leray E, Moreau T, Fromont A, et al. Epidemiology of multiple sclerosis. Rev Neurol (Paris). 2016 Jan;172(1):3–13.
  • Kabat EA, Moore DH, Landow H. An electrophoretic study of the protein components in cerebrospinal fluid and their relationship to the serum proteins. J Clin Invest. 1942 Sep;21(5):571–577.
  • Lehmann-Horn K, Kinzel S, Weber MS. Deciphering the role of B cells in multiple sclerosis-towards specific targeting of pathogenic function. Int J Mol Sci. 2017 Sep 23;18(10).
  • Weinshenker BG, O’Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999 Dec;46(6):878–886.
  • Dudesek A, Zettl UK. Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis. J Neurol. 2006 Sep;253(Suppl 5):V50–V58.
  • Rahmanzadeh R, Weber MS, Bruck W, et al. B cells in multiple sclerosis therapy-A comprehensive review. Acta Neurol Scand. 2018 Jun;137(6):544–556.
  • Monson NL, Cravens PD, Frohman EM, et al. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol. 2005 Feb;62(2):258–264.
  • Stuve O, Cepok S, Elias B, et al. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol. 2005 Oct;62(10):1620–1623.
  • Salzer J, Svenningsson R, Alping P, et al. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology. 2016 Nov 15;87(20):2074–2081.
  • Inc G Rituxan® (Rituximab) Prescribing Information. 2013.
  • Ltd H-LR. MabThera (Rituximab) Summary of Product Characteristics. 2009.
  • Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 Feb 14;358(7):676–688.
  • Hawker K, O’Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009 Oct;66(4):460–471.
  • Granqvist M, Boremalm M, Poorghobad A, et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol. 2018 Mar 1;75(3):320–327.
  • Hu Y, Nie H, Yu HH, et al. Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis. Autoimmun Rev. 2019 May;18(5):542–548.
  • Naegelin Y, Naegelin P, von Felten S, et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurol. 2019 Jan 7;76:274.
  • Barra ME, Soni D, Vo KH, et al. Experience with long-term rituximab use in a multiple sclerosis clinic. Mult Scler J Exp Transl Clin. 2016;2:2055217316672100.
  • Alldredge B, Jordan A, Imitola J, et al. Safety and efficacy of rituximab: experience of a single multiple sclerosis center. Clin Neuropharmacol. 2018 Mar/Apr;41(2):56–59.
  • Yamout BI, El-Ayoubi NK, Nicolas J, et al. Safety and efficacy of rituximab in multiple sclerosis: a retrospective observational study. J Immunol Res. 2018;2018:1–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.